Event Title

The Effect of Matrix Metalloproteinase Inhibition on PPARγ expression in 3T3-L1 Preadipocytes

Presenter Information

Jared Koval, Susquehanna University

Faculty Advisor

Dr. Thomas Peeler

Start Date

23-4-2019 4:00 PM

End Date

23-4-2019 5:00 PM

Description

Recently, new molecular pathways are being investigated to find potential treatments for obesity. One of the mechanisms being studied is the interaction between the extra cellular matrix (ECM) and adipocytes. The murine 3T3-L1 cell line has been commonly used as a model for adipogenesis in mammalian tissues. Despite extensive research, there is still little known about the ECM’s role in adipocyte differentiation. We investigated the roles of the ECM enzymes, matrix metalloproteinases (MMPs), on adipogenesis. Cells were treated throughout differentiation with the MMP inhibitor, ilomostat. . Expression of the essential protein, Peroxisome Proliferator-Activated Receptor gamma (PPARγ) was evaluated using Western Blotting. In addition, cells were treated with the PPARγ agonist, rosiglitazone, and others with both ilomostat and rosiglitazone. The results of our study will help to better understand the interactions between the ECM and adipose tissues and may help to find future treatments to obesity, diabetes, and other metabolic diseases.

This document is currently not available here.

Share

COinS
 
Apr 23rd, 4:00 PM Apr 23rd, 5:00 PM

The Effect of Matrix Metalloproteinase Inhibition on PPARγ expression in 3T3-L1 Preadipocytes

Recently, new molecular pathways are being investigated to find potential treatments for obesity. One of the mechanisms being studied is the interaction between the extra cellular matrix (ECM) and adipocytes. The murine 3T3-L1 cell line has been commonly used as a model for adipogenesis in mammalian tissues. Despite extensive research, there is still little known about the ECM’s role in adipocyte differentiation. We investigated the roles of the ECM enzymes, matrix metalloproteinases (MMPs), on adipogenesis. Cells were treated throughout differentiation with the MMP inhibitor, ilomostat. . Expression of the essential protein, Peroxisome Proliferator-Activated Receptor gamma (PPARγ) was evaluated using Western Blotting. In addition, cells were treated with the PPARγ agonist, rosiglitazone, and others with both ilomostat and rosiglitazone. The results of our study will help to better understand the interactions between the ECM and adipose tissues and may help to find future treatments to obesity, diabetes, and other metabolic diseases.